AN2 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANTX research report →
Range $9 – $9
Price Chart
About the company
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease.
- CEO
- Eric E. Easom
- IPO
- 2022
- Employees
- 21
- HQ
- Menlo Park, CA, US
Get TickerSpark's AI analysis on ANTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $182.60M
- P/E
- -4.74
- PEG
- -0.33
- P/S
- 0.00
- P/B
- 2.99
- EV/EBITDA
- -3.68
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -53.52%
- ROIC
- -51.01%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-38,109,000
- Net Income
- $-35,174,000+31.5%
- EPS
- $-1.16+32.6%
- OCF Growth
- +39.4%
- FCF Growth
- +39.4%
- 52W High
- $7.19
- 52W Low
- $1.00
- 50D MA
- $5.53
- 200D MA
- $3.80
- Beta
- -0.98
- RSI (14)
- 44
- Avg Volume
- 236.50K
No earnings-call transcripts are available for ANTX yet.
- Free Float
- 55.5%
- Shares Outstanding
- 36.02M
- Float Shares
- 19.98M
of shares held by institutions
52 13F filers
Buy/sell ratio 0.55. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vivo Capital, LLC | 3.15M | 0 |
| Commodore Capital LP | 2.93M | ▲ 599.97K |
| Millennium Management LLC | 2.32M | ▲ 96.19K |
| Blackrock, Inc. | 1.67M | ▲ 1.35M |
| Spruce Street Capital LP | 1.66M | 0 |
| Almitas Capital LLC | 1.47M | ▼ 10.00K |
| Vanguard Capital Management LLC | 1.24M | ▲ 227.63K |
| Vanguard Group Inc | 1.08M | 0 |
| Adage Capital Partners Gp, L.L.C. | 1.00M | 0 |
| Citadel Advisors LLC | 952.00K | ▲ 796.76K |
| Boxer Capital Management, LLC | 749.03K | 0 |
| Geode Capital Management, LLC | 697.81K | ▲ 411.26K |
Held by 86 ETFs
Biggest fund positions in ANTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Trenor Cameron C. III | other | 233,333 |
| Sep 15, 26 | Trenor Cameron C. III | other | 116,667 |
| Sep 9, 26 | Readnour Robin Shane | sell | 585 |
| Sep 9, 26 | Readnour Robin Shane | sell | 523 |
| Sep 3, 26 | Readnour Robin Shane | sell | 3,223 |
| Sep 8, 26 | Readnour Robin Shane | sell | 5,294 |
| Sep 3, 26 | Readnour Robin Shane | sell | 2,877 |
| Sep 8, 26 | Readnour Robin Shane | sell | 4,725 |
| Sep 1, 26 | Williams Sarah Joanne | sell | 272 |
| Sep 1, 26 | FitzPatrick Margaret M | buy | 2,098 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANTX coverage
Recent articles, reports, and earnings notes.
No research on ANTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANTX report →AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK
businesswire.com · Sep 28
AN2 Therapeutics: A Failed Drug Could Become A Major Value Driver
seekingalpha.com · Sep 22
AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)
businesswire.com · Sep 16
AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
businesswire.com · Aug 31
AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
businesswire.com · Aug 24
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
gurufocus.com · Aug 11
AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
businesswire.com · Aug 11
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of AN2 Therapeutics, Inc. (NASDAQ: ANTX)
prnewswire.com · Jul 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.